Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1691626
PUBLISHER: BCC Research | PRODUCT CODE: 1691626
Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
PUBLISHED:
PAGES: 160 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global market for CAR T-cell therapy is expected to grow from $4.6 billion in 2024 and projected to reach $25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.
The global CAR T-cell therapy market for Yescarta is expected to grow from $1.8 billion in 2024 and projected to reach $8.7 billion by the end of 2029, at a CAGR of 36.7% from 2024 to 2029.
The global CAR T-cell therapy market for Carvykti is expected to grow from $710 million in 2024 and projected to reach $5.9 billion by the end of 2029, at a CAGR of 52.6% from 2024 to 2029.
Report Scope
This report incorporates an in-depth analysis of CAR T-cell therapy's current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players' profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies' business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.
Report Includes
- 14 data tables and 71 additional tables
- Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
- Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
- Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry
- An analysis of patents, emerging trends and developments in the industry
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca
Product Code: BIO162C
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Market and Technology Background
- A Brief History of CAR T-Cell Therapy
- FDA Product Approvals
- Other CAR T-Cell Therapies
- Clinical Applications of CAR T-Cell Therapy
- Adoptive Cell Transfer (ACT) Technologies
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Increasing Incidence of Cancer
- Growing Investments and Funding in CAR T-Cell Therapy Research
- Robust R&D Pipeline
- Advances in Genetic Engineering
- Market Restraints
- Complex Legislative and Regulatory Procedures
- Alternative Products from Competitors
- Market Opportunities
- Growing Significance of Precision Medicine
- Expanding Applications for CAR T-Cell Therapy
- Market Challenges
- Complex Manufacturing and Supply Chain
- Reimbursement Challenges for CAR T-Cell Therapy
Chapter 4 Emerging Technologies and Clinical Trials
- Introduction
- Clinical Trials Being Conducted Globally
- Distribution of CAR T-Cell Clinical Trials in China
Chapter 5 Market Segmentation Analysis
- Key Takeaways
- Segmentation Breakdown
- Global Market for CAR T-Cell Therapy, by Product
- Yescarta
- Kymriah
- Tecartus
- Abecma
- Breyanzi
- Carvykti
- Global Market for CAR T-Cell Therapy, by Indication
- Geographic Breakdown
- Global Market for CAR T-Cell Therapy, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 6 Patent Review and New Developments
- Introduction
- Anticipated Increase in Patent Litigation on Customized Patient Treatments
- Company-specific Intellectual Property and Patent Information
- Amgen
- Avacta Life Sciences Ltd.
- Bluebird Bio
- Celgene Corp.
- Cellectis
- Celyad SA
- Editas Medicine Inc.
- Eureka Therapeutics Inc.
- iCell Gene Therapeutics
- Juno Therapeutics Inc. (A Celgene Co.)
- Noile-Immune Biotech
- Novartis AG
Chapter 7 Competitive Intelligence
- Ranking of Leading Players
- Strategic Considerations
Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective
- Introduction to ESG
- Role of ESG in the Pharma Industry
- ESG Performance Analysis
- Environmental
- Social
- Governance
- ESG Risk Ratings
- Conclusion
Chapter 9 Appendix
- Methodology
- Abbreviations
- References
- Company Profiles
- ABBVIE INC.
- ALLOGENE THERAPEUTICS
- AMGEN INC.
- ASTRAZENECA
- BLUEBIRD BIO INC.
- BRISTOL-MYERS SQUIBB CO.
- CELLECTIS S.A.
- EUREKA THERAPEUTICS INC.
- GILEAD SCIENCES INC.
- ICELL GENE THERAPEUTICS INC.
- JOHNSON & JOHNSON SERVICES INC.
- LES LABORATOIRES SERVIER
- NOVARTIS AG
- PFIZER INC.
- PROTHERAGEN INC.
Product Code: BIO162C
List of Tables
- Summary Table : Global Market for CAR T-Cell Therapy, by Product, Through 2029
- Table 1 : U.S. FDA-approved CAR T-cell Therapies, 2017-2022
- Table 2 : Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues
- Table 3 : Tumor-Associated Antigens of CAR T-Cell Targets
- Table 4 : Global Cancer Statistics, 2022
- Table 5 : Clinical Trials of CAR T-Cell Therapy, by Select Countries, January 2023
- Table 6 : CAR T-Cell Therapy Clinical Trials Distribution, by Investigators and Collaborators, January 2023
- Table 7 : Emerging CAR T-Cell Therapy Clinical Trials, by Company
- Table 8 : Clinical Trials on CD19 Directed CAR T Cells in the U.S.
- Table 9 : Examples of Clinical Trials on CD19-Directed CAR T Cells in China
- Table 10 : Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China
- Table 11 : Examples of Clinical Trials on CAR T Cells for Solid Tumors in China
- Table 12 : Clinical Trials on CAR T Cells with Fourth-Generation CARs in China
- Table 13 : Global Market for CAR T-Cell Therapy, by Product, Through 2029
- Table 14 : Global Market for CAR T-Cell Therapy, by Indication, Through 2029
- Table 15 : Clinical Trials of CAR T-cell Therapy in Other Indications
- Table 16 : Global Market for CAR T-Cell Therapy, by Region, Through 2029
- Table 17 : Bluebird Bio: Patents and Patent Applications, 2012-2021
- Table 18 : Celgene Corp.: Patents and Patent Applications, 2018-2021
- Table 19 : Cellectis: Patents and Patent Applications, 2018-2021
- Table 20 : Editas Medicine: Patent Applications, 2015-2021
- Table 21 : Eureka Therapeutics: Patent Applications, 2012-2021
- Table 22 : iCell Gene Therapeutics: Patent Applications, 2017-2019
- Table 23 : Juno Therapeutics Inc. and Memorial Sloan Kettering Cancer Center: Patents and Patent Applications, 2000-2021
- Table 24 : Noile-Immune Biotech Inc. Yamaguchi University Patent Applications, 2017
- Table 25 : Novartis AG and University of Pennsylvania: Patents and Patent Applications, 2013-2021
- Table 26 : Leading Companies in the CAR T-Cell Therapy Market, 2023
- Table 27 : Focus Areas in ESG Metrics
- Table 28 : ESG Risk Rankings for CAR T-Cell Therapy Companies, 2024*
- Table 29 : Abbreviations Used in this Report
- Table 30 : AbbVie Inc.: Company Snapshot
- Table 31 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
- Table 32 : AbbVie Inc.: Product Portfolio
- Table 33 : AbbVie Inc.: News/Key Developments, 2023-2024
- Table 34 : Allogene Therapeutics: Company Snapshot
- Table 35 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
- Table 36 : Allogene Therapeutics: Product Portfolio
- Table 37 : Allogene Therapeutics: News/Key Developments, 2024
- Table 38 : Amgen Inc.: Company Snapshot
- Table 39 : Amgen Inc.: Financial Performance, FY 2022 and 2023
- Table 40 : Amgen Inc.: Product Portfolio
- Table 41 : Amgen Inc.: News/Key Developments, 2024
- Table 42 : AstraZeneca: Company Snapshot
- Table 43 : AstraZeneca: Financial Performance, FY 2022 and 2023
- Table 44 : AstraZeneca: Product Portfolio
- Table 45 : AstraZeneca: News/Key Developments, 2023-2024
- Table 46 : Bluebird Bio Inc.: Company Snapshot
- Table 47 : Bluebird Bio Inc.: Financial Performance, FY 2022 and 2023
- Table 48 : Bluebird Bio Inc.: Product Portfolio
- Table 49 : Bluebird Bio Inc.: News/Key Developments, 2020-2022
- Table 50 : Bristol-Myers Squibb Co.: Company Snapshot
- Table 51 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
- Table 52 : Bristol-Myers Squibb Co.: Product Portfolio
- Table 53 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2024
- Table 54 : Cellectis S.A.: Company Snapshot
- Table 55 : Cellectis S.A.: Financial Performance, FY 2022 and 2023
- Table 56 : Cellectis S.A.: Product Portfolio
- Table 57 : Cellectis S.A.: News/Key Developments, 2023-2024
- Table 58 : Eureka Therapeutics Inc.: Company Snapshot
- Table 59 : Eureka Therapeutics Inc: Product Portfolio
- Table 60 : Eureka Therapeutics Inc.: News/Key Developments, 2023-2024
- Table 61 : Gilead Sciences Inc.: Company Snapshot
- Table 62 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
- Table 63 : Gilead Sciences Inc.: Product Portfolio
- Table 64 : Gilead Sciences Inc.: News/Key Developments, 2022-2024
- Table 65 : iCell Gene Therapeutics Inc.: Company Snapshot
- Table 66 : iCell Gene Therapeutics Inc: Product Portfolio
- Table 67 : iCell Gene Therapeutics Inc.: News/Key Developments, 2024
- Table 68 : Johnson & Johnson Services Inc.: Company Snapshot
- Table 69 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
- Table 70 : Johnson & Johnson Services Inc.: Product Portfolio
- Table 71 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
- Table 72 : Les Laboratoires Servier: Company Snapshot
- Table 73 : Les Laboratoires Servier: Product Portfolio
- Table 74 : Les Laboratoires Servier: News/Key Developments, 2024
- Table 75 : Novartis AG: Company Snapshot
- Table 76 : Novartis AG: Financial Performance, FY 2022 and 2023
- Table 77 : Novartis AG: Product Portfolio
- Table 78 : Novartis AG: News/Key Developments, 2021-2024
- Table 79 : Pfizer Inc.: Company Snapshot
- Table 80 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
- Table 81 : Pfizer Inc.: Product Portfolio
- Table 82 : Pfizer Inc.: News/Key Developments, 2023
- Table 83 : Protheragen Inc.: Company Snapshot
- Table 84 : Protheragen Inc.: Product Portfolio
List of Figures
- Summary Figure : Global Market for CAR T-Cell Therapy, by Product, 2022-2029
- Figure 1 : Historical Development of CAR T-Cell Therapy, 1992-2017
- Figure 2 : Snapshot of the Market Dynamics for CAR T-Cell Therapy
- Figure 3 : Estimated New Cancer Cases, 2022, 2045 and 2050
- Figure 4 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Status, January 2023
- Figure 5 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Study Phase, January 2023
- Figure 6 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Investigator Type, January 2023
- Figure 7 : Global CAR T-Cell Clinical Trial Activity, by Study Start Date and Phase, 2021-2024
- Figure 8 : Global Market Shares of CAR T-Cell Therapy, by Product, 2024
- Figure 9 : Global Market Shares for Yescarta, by Region, 2024
- Figure 10 : Global Market Shares for Kymriah, by Region, 2024
- Figure 11 : Global Market Shares for Tecartus, by Region, 2024
- Figure 12 : Global Market Shares for Abecma, by Region, 2024
- Figure 13 : Global Market Shares for Breyanzi, by Region, 2024
- Figure 14 : Global Market Shares for Carvykti, by Region, 2024
- Figure 15 : Global Market Shares of CAR T-Cells Therapy, by Indication, 2024
- Figure 16 : Global Market Shares of CAR T-Cell Therapy, by Region, 2024
- Figure 17 : Strategic Considerations
- Figure 18 : How a Strong ESG Proposition Benefits Businesses
- Figure 19 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 20 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 21 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 22 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 23 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
- Figure 24 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
- Figure 25 : Bristol Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
- Figure 26 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
- Figure 27 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 28 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 29 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 30 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
- Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
- Figure 33 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 34 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.